Table 3 Inclusion of biologic medicines in the WHO Model List and national essential medicines lists
From: Biologic medicine inclusion in 138 national essential medicines lists
Biologic medicine of interest | Inclusion in 2019 WHO Model List of Essential Medications (Yes/No) | Inclusion in 2019 WHO Model List of Essential Medicines for Children (Yes/No) | Total number of countries listing biologic medicine of interest (%) |
|---|---|---|---|
Abatacept | No | No | 4 (2.9) |
Adalimumab | Yes | Yes | 20 (14.49) |
Alemtuzumab | No | No | 12 (8.7) |
Anakinra | No | No | 5 (3.62) |
Belimumab | No | No | 2 (1.45) |
Canakinumab | No | No | 2 (1.45) |
Certolizumab | Yes | No | 8 (5.8) |
Eculizumab | No | No | 3 (2.17) |
Etanercept | Yes | Yes | 28 (20.29) |
Golimumab | Yes | No | 6 (4.35) |
Infliximab | Yes | Yes | 22 (15.94) |
Rituximab | Yes | Yes | 42 (30.43) |
Tocilizumab | No | No | 11 (7.97) |
Ustekinumab | No | No | 6 (4.35) |